Advertisement

Picture Berlin Partner HealthCapital Voices from Berlin-Brandenburg 650x80px
Document › Details

Home Biosciences S.A.S.. (11/9/21). "Press Release: Home Biosciences Closes $15 Million Seed Financing Led by Redmile Group and Sofinnova Partners". Paris.

Organisations Organisation Home Biosciences S.A.S.
  Group Home Biosciences (Group)
  Organisation 2 Redmile Group LLC
Products Product BIOTECH
  Product 2 venture capital
Index terms Index term Home Biosciences–SEVERAL: investment, 202111 seed financing round $15m led by Redmile Group + Sofinnova Partners
  Index term 2 Home Biosciences–Sofinnova: investment, 202111 seed financing round totalling $15m incl co-lead investor Sofinnova Partners
Persons Person Schilansky, David (Home Biosciences 202111 CEO + Co-Founder before DBV Technologies + Lysogene)
  Person 2 Papiernik, Antoine (Sofinnova Partners 201703 Managing Partner + Chairman joined 1997)
     


Home Biosciences, Europe’s first venture builder fully dedicated to biotech, announced today a $15 million Seed financing led by Redmile Group and Sofinnova Partners.

Home Biosciences is the partner of choice for academics and scientists to transform their innovation into life changing therapies for patients. Every step of the way, Home Biosciences works together with leading scientific teams to build and grow sustainable businesses, by assembling the right expertise and structure. Each project is housed in a dedicated entity, a subsidiary, fully financed by Home Biosciences and led by teams entirely focused on the day-to-day execution of its projects with oversight from the Home Biosciences core management team.

"We are pleased to have such strong support from Redmile Group and Sofinnova Partners, two landmark investors in biotech, who recognize our potential to build a new type of biotech company, out of European science" said David Schilansky and Magali Richard, co-founders of Home-Biosciences. “Our ambition is to build a fully-fledged biotech company with an asset-centric operational model that aims to increase agility and R&D productivity. With the strong support of our shareholders, we look forward to leverage best-in-class science that will ultimately allow us to discover and deliver a new wave of first-in-class therapies.”

Proceeds from the financing will be used to accelerate the development of Home Biosciences’ pipeline while further strengthening its team. Specifically, the round will allow the company to advance its first venture, One Biosciences, as well as build a second one and a strong pipeline of projects. One Biosciences is focused on generating precision medicines by leveraging the power of single-cell technologies.

“Home Biosciences is pioneering an innovative model that fills an important gap in the European biotech ecosystem," said Antoine Papiernik, Managing Partner at Sofinnova Partners. “We are delighted to join forces with Redmile Group in supporting Europe’s first biotech venture builder in its mission to provide financial support and operational guidance, to create the groundbreaking therapies of the future.”

In connection with the Seed round, Ming Fang, a Managing Director of Redmile Group, and Antoine Papiernik, Managing Partner at Sofinnova Partners, will serve on the Board of Directors. They will join David Schilansky and Magali Richard, co-founders of Home Biosciences. An independent member of the Board is expected to be appointed in the near future.


About Home Biosciences

Home Biosciences is Europe’s first venture builder fully dedicated to biotech. Home Biosciences is the partner of choice for academics and scientists to transform their innovation into life changing therapies for patients. Every step of the way, Home Biosciences works with leading scientific teams to build and grow sustainable businesses, by assembling the right expertise and structure. With each of its projects housed in dedicated ventures and fully financed by Home Biosciences, its operating model allows full focus of its teams on scientific and operational excellence and rapid execution to significantly expedite and de-risk their discovery and development paths.

For more information, visit: www.homebiosciences.com


Contacts

Home Biosciences
David Schilansky & Magali Richard
contact@homebiosciences.com

   
Record changed: 2021-11-16

Advertisement

Picture Kentro Design Is Key to Your Success Berlin 650x100px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture EBD Group BioTech Showcase 2022 For Investors 650x300




» top